Health-care companies fell as traders retreated from high-risk niches such as obesity-drug makers and biotech firms.

Shares of Viking Therapeutics, Novo Nordisk and Eli Lilly retreated. The iShares Nasdaq Biotechnology exchange-traded fund, which started the week in positive territory for 2024, is now down 3% for the year to date because of risk aversion.

Lonza Group appointed Wolfgang Wienand, who is currently chief executive at smaller Swiss peer Siegfried Holding, as chief executive.


Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

04-02-24 1756ET